Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and aspirin could be effective in reducing the risk of Alzheimer's disease, a new study suggests.

A report published in the medical journal of the American Academy of Neurology presented findings taken from the collated data of six different studies investigating the benefits of NSAIDs in relation to the development of dementia.

Neurologists found that patients who used NSAIDs had 23 per cent lower risk of developing Alzheimer's disease compared to those who never used NSAIDs.

Study author Dr Peter P Zandi, from Johns Hopkins Bloomberg School of Public Health in Baltimore, commented: "The NSAID group that includes ibuprofen was thought to target a certain type of plaque in the brain found in Alzheimer's patients."

Experts have previously debated whether a certain group of NSAIDs that includes ibuprofen may be more beneficial than another group that includes naproxen and aspirin.

However, the latest findings showed that the risk reduction of developing Alzheimer's was not dependent on the type of NSAID taken.

According to non-profit organisation Alzheimer's Europe, between 50 and 70 per cent of patients with dementia are suffering from Alzheimer's disease.

Login and visit the Alzheimer's Disease Knowledge Centre

• Blood sugar warning for the prevention of Alzheimer's 30/12/08
• Brain starvation seems to trigger Alzheimer's, study suggests 29/12/08
• Plans for new Alzheimer's clinics unveiled 24/12/08
• Cardiovascular proteins found to work together to speed up Alzheimer's 22/12/08
• Research looks at strategy games in the prevention of cognitive deterioration 12/12/08

• EBIXA 10mg film-coated tablets - 50.88%
  Treatment of patients with moderately severe to severe Alzheimers disease ...
  
  
• CERETEC - 26.56%
  ... the diagnosis of abnormalities of regional cerebral blood flow, such as those occurring following stroke and other cerebrovascular disease, epilepsy, Alzheimer's Disease and other forms of dementia, transient ischaemic attack, migraine and tumours of the brain. (ii) Technetium [99mTc] Exametazime ...
  
  
• EBIXA 10 mg/g oral drops, solution - 25.26%
  Treatment of patients with moderate to severe Alzheimer's disease ...
  
  
• EXELON Capsules - 25.26%
  Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease ...
  
  
• CEREZYME 400 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...
  
  
• CEREZYME 200 U Solution for Infusion - 25.04%
  ... disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: • anaemia after exclusion of other causes, such as iron deficiency • thrombocytopenia • bone disease ...